Survival and changes in mean body mass of whole-body irradiated mice were determined to examine the radioprotectant activity of 5-diethylsulfonamoylsalicylatocopper(II) [Cu(II) (5-DESS)]. One of four groups of 25 female C57BL/6 mice were treated subcutaneously (sc)with 0, 10, 20, 40, 60, 80, 100, or 120 gmol Cu(II)(5-DESS)/kg of body mass 3 hours before exposure to 8.0 Gy, gamma irradiation. In this paradigm, doses of Cu(II)(5-DESS) increased survival up to 92% above vehicle-treated control mice (P 0.008). Mean body mass determinations revealed that mice treated with 80 to 120 gmol Cu(II)(5-DESS)/kg of body mass exhibited a smaller decrease in body mass than other complex-treated groups. These results support the hypothesis that Cu(II)(5-DESS)
INTRODUCTION
Protecting tissues from harmful effects of ionizing radiation or facilitating recovery from radiation injury are important in reducing injurious aspects of accidental, environmental, occupational, and therapeutic exposure to radiation. Agents used for these purposes are of particular importance with regard to facilitating manned space travel enabling prophylaxis or treatment of solar radiation injury, treatment of radiation injury due to exposure to radioactive material from electric power generating facilities, as well as gamma-ray, x-ray, and ultraviolet electromagnetic radiation generated by high voltage power distribution lines, radiotherapy of neoplastic tumors, and electromagnetic radiation due to the transparency of the ozone layer [1] . Radioprotector and radiorecovery agents, agents administered after radiation injury [2] , are essential in planning the manned space program and decreasing the adverse health effects of intended and accidental exposure to radiation.
In 1942, Dale observed that addition of colloidal sulfur and thiourea to an aqueous solution of carboxypeptidase prior to x-irradiation protected the enzyme from inactivation [3] . Since this report, thousands of compounds have been screened for use as radioprotectants [4, 5] . The best known and most widely studied of these compounds is S-2-(3-aminopropylamino)ethyl phosphorothiotic acid (WR-2721). However, WR-2721 is plagued by two major problems, which are associated with all aminothiol-based compounds, high toxicity and an inability to substantially increase survival when administered after irradiation [6] .
The discovery that a cytostolic essential metalloelement-dependent enzyme, dicopper(II)dizinc(II) Superoxide Dismutase (CuZnSOD), increased survival of lethally irradiated mice when administered both one hour before and after irradiation [7] , suggested a new approach to radiation protection. This new approach was consistent with the recognition that radiation injury is increased in the presence of oxygen and the formation of superoxide [8, 9] .
There is a rich history describing the occasional use of essential metalloelements, including Cu, as radioprotective agents [5, 10] . Most recently, the radioprotective effect of dicopper tetrakis-(3,5-diisopropylsalicylate), [Cu(II)z(3,5-DIPS)4]. [Cu(II)z(3,5-DIPS)4] was examined based upon its SOD-mimetic activity [11] . It has subsequently been shown that Cu(II)z(3,5-DIPS)4 is effective when given intraperitoneally, subcutaneously, or orally at nontoxic doses either before or after irradiation [12] [13] [14] . Doses of Cu(II)z(3,5-DIPS)4 used in reported studies range from one-fifth to one-hundredth of the acutely toxic dose for male or female mice respectively 12].
Radioprotectant Activity of Since Cu(II)z(3,5-DIPS)4 is a non-antigenic, SOD-mimetic complex [15] we addressed the question as to whether or not other non-antigenic, SOD-mimetic copper complexes might also be effective radioprotectants. Toward this end we studied the radioprotectant efficacy of another SOD-mimetic, copper(II) 5 One liter of a 1.4% mass/volume polyvinyl alcohol (Sigma) was prepared by dissolving 14 grams in 900 ml saline at 90C with stirring, cooling to room temperature, and diluting to 1000 ml after removal of the stirring bar.
Solutions of Cu(II)(5-DESS) were prepared as follows. The complex (23 rag, 64 lamol) was first wetted with 1.6 ml of propylene glycol in a glass Potter-Elvehjem homogenizer with a Teflon pestle. The resulting emerald green solution was transferred to a graduated cylinder with 1.4% polyvinyl alcohol in saline, used to rinse the homogenizer, to a total volume of 40 ml, and vortex stirred. This slow dilution produced a light-green colored true solution. A volume of 0.5 ml of this solution contained 0.8 tmol of complex and provided the 40 tmol/kg of body mass dose of Cu(II)(5-DESS). Ten or five ml of this solution was diluted with 10 or 15 ml of complete vehicle (4% propylene glycol and 1.4% polyvinyl alcohol in saline), respectively and vortex stirred to obtain solutions containing 20 or 10 lamol/kg of body mass dose per 0.5 ml of solution.
Solutions of 40, 60, or 80 lamol/kg of body mass were prepared by first wetting the complex (115 mg, 320 mol) with 4 ml of propylene glycol in a 10 ml beaker. This solution was stirred and transferred to a graduated cylinder with 1.4% polyvinyl alcohol in saline to a total volume of 100 ml and vortex stirred. A volume of 0.5 m contained 1.6 mol of complex and provided 80 lamol Cu(II)(5-DESS)/kg of body mass. Fifteen ml or 10 ml of the 3.2 lamol per ml solution was diluted with 5 ml or 10 ml of complete vehicle to obtain solutions containing 1.2 lamol or 0.8 mol per 0.5 ml of solution which provided 60 mol or 40 lamol Cu(II)(5-DESS)/kg of body mass Solutions of 1.6, 2.0, 2.4 mol per 0.5 ml intended to administer 80, 100, 120 mol Cu(II)(5-DESS)/kg of body mass were prepared by fh'st wetting the complex (69 mg, 196 lamol) with 1.6 ml of propylene glycol in a 10 ml beaker and then the contents of the beaker transferred to a graduated cylinder and vortex stirred with enough 1.4% polyvinyl alcohol to make 40 ml of a 2.40 mol per 0.5 ml of solution, providing 120 tmol Cu(II)(5-DESS)/kg of body mass.
Fifteen ml of this solution was then diluted with 3 ml of complete vehicle and vortex stirred to obtain 18 ml containing 2.0 tmol of Cu(II)(5-DESS) per 0.5 ml, providing a dose of 100 lamol/kg of body mass. Twelve ml of the 2.4-lamol per 0.5 ml solution was then diluted with 6 ml of complete vehicle and vortex stirred to obtain 18 ml of a 1.6 mol per 0. 
RESULTS
As shown in Figure 1 , treatment with 20 or 40 lamol Cu(II)(5-DESS)/kg of body mass caused a modest increase in survival. These small and not statistically significant increases in survival were 15% or 30%, respectively, greater than vehicle-treated mice. It is noteworthy that the duration of 100% survival following irradiation increased with increasing dose of complex. Repeating this study using doses of 40, 60, or 80 ktmol/kg of body mass caused greater increases in survival (Figure 2) to 66%, 66%, or 111% (P--0.01) respectively above vehicle-treated mice. Treatment with doses of 80, 100, or 120 lamol Cu(II)(5-DESS)/kg of body mass increased survival however only the 120 mol/kg dose produced a statistically significant (P=0.008) increase in survival ( Figure 3 ) and again it is clear that the duration of 100% survival following irradiation increased with increasing dose of complex. These survival results are summarized in Table I . DISCUSSION Doses of Cu(II)(5-DESS) used in this study ranged from 10 to 120gmol/kg of body mass or 0.2 to 2.4 gmol/mouse. All of these doses were non-toxic as evidenced by the lack of acute toxicity associated death in complex-treated groups prior to deaths occurring in vehicle-treated groups.
Since Cu(II)(5-DESS) increases survival when given prior to irradiation to facilitate physiological and biochemical responses following radiation injury, it is termed a radioprotective agent [2] . It seems improbable that radioprotectant activities of this complex are exclusively due to its superoxide dismutase-mimetic activity. Doses used in treatment would appear to be insufficient to be propitiously distributed to all tissues of 15 Subsequently, many copper complexes including salicylates have been found to have a variety of antiinflammatory activities including: anti-polyarthritic, anti-ulcer, anti-convulsant, anti-cancer, analgesic, anti-diabetic, anti-carcinogenic, anti-mutagenic, anti-inflammatory bowel syndrome, prevention of ischemia-reperfusion injury, radioprotectant, and radiorecovery activites [18] [19] [20] . Since whole-body radiation injury is a model of whole-body inflammatory disease, the demonstration of radioprotectant activity for Cu(II)(5-DESS) is a demonstration of antiinflammatory activity for this complex. Cu(II)(5-DESS) may also have other anti-inflammatory activities as well.
Studies of biochemical systems that mechanistically account for these antiinflammatory activities have revieled that copper complexes modulate: lysyl oxidases, eicosanoid syntheses and arachidonate metabolism, CuzZn2 SODs and demonstrate SOD-mimetic activity, stabilization of synovial and polymorphonuclear leukocyte lysosomal membranes, histaminic activity, lymphocyte mitogenic and chemotactic responses, stabilization of gamma-gobulin, GSH status, GSH-S-transferase, preprothrombin carboxylase, cytochrome P-450 monooxygenases, and/or NADPH-dependent P-450 reductases, 2-oxoglutarate-dependent hydroxylase, lipid peroxidation, angiogensis, and luteinizing hormone-releasing hormone secretion [18 and citations therein] as well as down-regulate nitric oxide synthase [21 ] .
